$213.00
-9.26[-4.17%]
At close: Apr 19
$213.00
0[0.00%]
After Hours: 4:14PM EDT
Madrigal Pharmaceuticals
(NASDAQ:MDGL)Madrigal Pharmaceuticals Stock (NASDAQ:MDGL), Analyst Ratings, Price Targets, Predictions
Madrigal Pharmaceuticals Inc has a consensus price target of $346, established from looking at the 50 latest analyst ratings. The last 3 analyst ratings were released from Evercore ISI Group, UBS, and TD Cowen on March 20, 2024, March 15, 2024, and March 15, 2024. With an average price target of $401.67 between Evercore ISI Group, UBS, and TD Cowen, there's an implied 88.58% upside for Madrigal Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Evercore ISI Group
UBS
TD Cowen
B. Riley Securities
Citigroup
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Madrigal Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/20/2024 | MDGL | Buy Now | Madrigal Pharmaceuticals | $213.00 | 90.14% | Evercore ISI Group | Liisa Bayko | $325 → $405 | Maintains | Outperform | Get Alert |
| 03/15/2024 | MDGL | Buy Now | Madrigal Pharmaceuticals | $213.00 | 92.49% | UBS | Eliana Merle | $337 → $410 | Maintains | Buy | Get Alert |
| 03/15/2024 | MDGL | Buy Now | Madrigal Pharmaceuticals | $213.00 | 83.1% | TD Cowen | Ritu Baral | $349 → $390 | Maintains | Outperform | Get Alert |
| 03/15/2024 | MDGL | Buy Now | Madrigal Pharmaceuticals | $213.00 | 26.76% | B. Riley Securities | Mayank Mamtani | $155 → $270 | Upgrade | Sell → Neutral | Get Alert |
| 03/15/2024 | MDGL | Buy Now | Madrigal Pharmaceuticals | $213.00 | 82.63% | Citigroup | David Lebovitz | $382 → $389 | Maintains | Buy | Get Alert |
| 03/15/2024 | MDGL | Buy Now | Madrigal Pharmaceuticals | $213.00 | 86.38% | JMP Securities | Jonathan Wolleben | — | Maintains | Outperform | Get Alert |
| 03/15/2024 | MDGL | Buy Now | Madrigal Pharmaceuticals | $213.00 | 76.06% | Oppenheimer | Jay Olson | $320 → $375 | Maintains | Outperform | Get Alert |
| 03/15/2024 | MDGL | Buy Now | Madrigal Pharmaceuticals | $213.00 | 77% | Canaccord Genuity | Edward Nash | $338 → $377 | Maintains | Buy | Get Alert |
| 03/15/2024 | MDGL | Buy Now | Madrigal Pharmaceuticals | $213.00 | 99.53% | HC Wainwright & Co. | Ed Arce | $405 → $425 | Maintains | Buy | Get Alert |
| 03/14/2024 | MDGL | Buy Now | Madrigal Pharmaceuticals | $213.00 | 57.75% | Piper Sandler | Yasmeen Rahimi | → $336 | Reiterates | Overweight → Overweight | Get Alert |
| 03/12/2024 | MDGL | Buy Now | Madrigal Pharmaceuticals | $213.00 | 90.14% | HC Wainwright & Co. | Ed Arce | $275 → $405 | Maintains | Buy | Get Alert |
| 03/08/2024 | MDGL | Buy Now | Madrigal Pharmaceuticals | $213.00 | 58.69% | Canaccord Genuity | Edward Nash | $336 → $338 | Maintains | Buy | Get Alert |
| 03/06/2024 | MDGL | Buy Now | Madrigal Pharmaceuticals | $213.00 | 79.34% | Citigroup | David Lebowitz | → $382 | Initiates | → Buy | Get Alert |
| 03/01/2024 | MDGL | Buy Now | Madrigal Pharmaceuticals | $213.00 | 50.23% | Oppenheimer | Jay Olson | $300 → $320 | Maintains | Outperform | Get Alert |
| 02/27/2024 | MDGL | Buy Now | Madrigal Pharmaceuticals | $213.00 | -27.23% | B. Riley Securities | Mayank Mamtani | $204 → $155 | Downgrade | Neutral → Sell | Get Alert |
| 02/26/2024 | MDGL | Buy Now | Madrigal Pharmaceuticals | $213.00 | -27.23% | B. Riley Securities | Mayank Mamtani | → $155 | Downgrade | Neutral → Sell | Get Alert |
| 02/23/2024 | MDGL | Buy Now | Madrigal Pharmaceuticals | $213.00 | 62.91% | JMP Securities | Jonathan Wolleben | → $347 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/16/2024 | MDGL | Buy Now | Madrigal Pharmaceuticals | $213.00 | 62.91% | JMP Securities | Jonathan Wolleben | → $347 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/24/2024 | MDGL | Buy Now | Madrigal Pharmaceuticals | $213.00 | 57.75% | Piper Sandler | Yasmeen Rahimi | $305 → $336 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Madrigal Pharmaceuticals (MDGL)?
The latest price target for Madrigal Pharmaceuticals (NASDAQ: MDGL) was reported by Evercore ISI Group on March 20, 2024. The analyst firm set a price target for $405.00 expecting MDGL to rise to within 12 months (a possible 90.14% upside). 30 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Madrigal Pharmaceuticals (MDGL)?
The latest analyst rating for Madrigal Pharmaceuticals (NASDAQ: MDGL) was provided by Evercore ISI Group, and Madrigal Pharmaceuticals maintained their outperform rating.
When was the last upgrade for Madrigal Pharmaceuticals (MDGL)?
The last upgrade for Madrigal Pharmaceuticals Inc happened on March 15, 2024 when B. Riley Securities raised their price target to $270. B. Riley Securities previously had a sell for Madrigal Pharmaceuticals Inc.
When was the last downgrade for Madrigal Pharmaceuticals (MDGL)?
The last downgrade for Madrigal Pharmaceuticals Inc happened on February 27, 2024 when B. Riley Securities changed their price target from $204 to $155 for Madrigal Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Madrigal Pharmaceuticals (MDGL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Madrigal Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Madrigal Pharmaceuticals was filed on March 20, 2024 so you should expect the next rating to be made available sometime around March 20, 2025.
Is the Analyst Rating Madrigal Pharmaceuticals (MDGL) correct?
While ratings are subjective and will change, the latest Madrigal Pharmaceuticals (MDGL) rating was a maintained with a price target of $325.00 to $405.00. The current price Madrigal Pharmaceuticals (MDGL) is trading at is $213.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.